Department of Orthopedic Surgery, Osaka Medical and Pharmaceutical University, Japan.
Department of Orthopedic Surgery, Osaka Medical and Pharmaceutical University, Japan.
Knee. 2022 Oct;38:42-49. doi: 10.1016/j.knee.2022.07.006. Epub 2022 Jul 28.
BACKGROUND: Postoperative pain management is essential for patient satisfaction; however, no reports have described the effect of perioperative duloxetine administration on the postoperative pain management following knee surgery. This study aimed to determine whether perioperative duloxetine administration reduces pain following high tibial osteotomy. METHODS: In this prospective clinical trial, 35 and 33 patients receiving (40 mg/day) and not receiving duloxetine (control), respectively were enrolled. The knee pain and quality of recovery were evaluated using the numeric rating scale (NRS) scores, the frequency of analgesic drugs used, and patient-reported outcome measures, including the NRS score at rest and the Knee Injury and Osteoarthritis Outcome Score (KOOS), were compared between the groups. RESULTS: The NRS scores of the duloxetine group (D) were significantly reduced compared with those of the control group (C) on postoperative day 1 (D:3.8 vs C:5.1, p = 0.022), day 7 (D:2.1 vs C:2.9, p = 0.021), and day 14 (D:1.6 vs C:2.9, p = 0.001). Non-steroidal anti-inflammatory drug administration was significantly lower in the duloxetine group than in the control group (p < 0.001). Although the KOOS score was not significantly different in several subcategories at the pre- and postoperative time-points, the Function in Sport subcategory of the KOOS was significantly improved in the duloxetine group compared with that in the control group at 3 months postoperatively (p < 0.05). CONCLUSION: Perioperative use of duloxetine from 2 weeks before surgery to 2 weeks after surgery is advantageous in perioperative pain management and KOOS improvement following high tibial osteotomy.
背景:术后疼痛管理对患者满意度至关重要;然而,目前尚无研究报告描述围手术期度洛西汀给药对膝关节手术后疼痛管理的影响。本研究旨在确定围手术期度洛西汀给药是否能减轻高胫骨截骨术后的疼痛。
方法:在这项前瞻性临床试验中,分别纳入了 35 例和 33 例接受(40mg/天)和不接受度洛西汀(对照组)治疗的患者。使用数字评分量表(NRS)评分评估膝关节疼痛和恢复质量,比较两组患者的 NRS 静息评分、使用镇痛药的频率和患者报告的结局测量指标,包括 NRS 评分和膝关节损伤和骨关节炎结果评分(KOOS)。
结果:与对照组(C)相比,度洛西汀组(D)的 NRS 评分在术后第 1 天(D:3.8 分 vs C:5.1 分,p=0.022)、第 7 天(D:2.1 分 vs C:2.9 分,p=0.021)和第 14 天(D:1.6 分 vs C:2.9 分,p=0.001)显著降低。度洛西汀组非甾体抗炎药的使用明显低于对照组(p<0.001)。虽然在术前和术后时间点,KOOS 评分在几个亚组中没有显著差异,但在术后 3 个月时,度洛西汀组的 KOOS 运动功能亚组明显优于对照组(p<0.05)。
结论:从术前 2 周至术后 2 周使用度洛西汀对高胫骨截骨术后围手术期疼痛管理和 KOOS 改善有益。
Eur J Orthop Surg Traumatol. 2024-7
Eur J Orthop Surg Traumatol. 2024-7
Knee Surg Sports Traumatol Arthrosc. 2023-12